On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route.

The HSA secured access to COVID-19 Vaccine Moderna through a supply agreement announced on Dec. 14, 2020. The authorization was based on the totality of scientific evidence shared by the Company, including a data analysis from the pivotal Phase 3 clinical study announced Nov. 30, 2020.